Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $92.60 Average PT from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $93.33.

A number of equities research analysts have weighed in on PBH shares. DA Davidson lifted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, Royal Bank of Canada boosted their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its position in shares of Prestige Consumer Healthcare by 3.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after purchasing an additional 49,331 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after purchasing an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Invesco Ltd. raised its position in shares of Prestige Consumer Healthcare by 2.4% during the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after purchasing an additional 24,392 shares during the last quarter. Finally, Congress Asset Management Co. raised its position in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after purchasing an additional 43,619 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $84.12 on Wednesday. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The stock’s 50 day moving average is $82.46 and its two-hundred day moving average is $78.59. The firm has a market capitalization of $4.17 billion, a PE ratio of 19.70, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.